Analyst Thibault Boutherin from Morgan Stanley maintained a Hold rating on Galderma Group AG and keeping the price target at CHF135.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Thibault Boutherin’s rating is based on Galderma Group AG’s recent performance and future prospects. The company demonstrated a strong third-quarter performance, with a notable increase in sales driven by its injectable aesthetics and Nemluvio products. The successful launch of new products and market share gains in both the US and international markets contributed to this growth.
Despite these positive developments, Boutherin’s Hold rating suggests a cautious approach, possibly due to the overall market softness and the need for continued investment in growth initiatives. While the company has upgraded its FY25 guidance, indicating confidence in its future performance, the Hold rating reflects a balanced view, considering both the potential for growth and the challenges that may lie ahead.